. Author manuscript; available in PMC: 2015 Jul 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Mar 15;20(7):951–959. doi: 10.1016/j.bbmt.2014.03.014

Table 3.

Studies on outcomes of autologous hematopoietic cell transplantation for follicular lymphoma with histologic transformation

STUDY Years of HCT	N	AGE Median (range) years	tFL Definition	PFS	OS	NRM	COMMENTS
PRE RITUXIMAB ERA
Williams¹⁷ EBMT Retrospective 1982–1995	50 auto HCT	45 (28–61)	FL→DLBCL or any high grade lymphoma	2y 40% 5y 30%	2y 60% 5y 51%	18%	Improved survival if chemosensitive at HCT. Same outcomes for FL, de novo relapsed DLBCL and transformed lymphoma in matched controlled analysis.
Friedberg¹⁸ Retrospective 1982–1997	27 auto HCT	44 (29–58)	FL→DLBCL CLL→DLBCL	5y 46%	5y 58%	0	All relapses after autoHCT were DLBCL. tFL within 18 months from diagnosis had better OS.
Eide³¹ Prospective Phase 2 1991–2007	30 auto HCT	55 (31–65)	FL or MZL →DLBCL or between DLBCL and BL, composite lymphoma	5y 32%	5y 47%	7%	Plateau on PFS after 40 months at 30%.
RITUXIMAB ERA
Hamadani¹⁶ Retrospective 1991–2007	24 auto HCT	56 (47–68)	FL→DLBCL	3y 40%	3y 52%	8%	Improved PFS in 62% of patients with rituximab in treatment course. Chemosensitivity at HCT had no effect on outcomes after HCT.
Ban-Hoefen³⁰ Retrospective 1998–2010	18 auto HCT	58 (40–65)	FL or MZL→DLBCL	2y 59%	2y 82%	0	Improved outcomes compared to historical pre-rituximab cohorts.¹⁷
Villa³² CBMTG Retrospective 2001–2010	97 auto HCT	56 (32–66)	FL→DLBCL or BL	5y 55%	5y 57%	5%	AutoHCT had better PFS/OS than rituximab-chemoRx.
Current study Retrospective 1990–2009	108 auto HCT	56 (19–74)	FL→DLBCL	5y 36%	5y 50%	8%	No impact of chemosensitivity or prior rituximab use on outcomes.

Abbreviations for Tables 3 and 4: OS overall survival, PFS progression free survival, NRM non-relapse-mortality, N number of patients evaluated, Y year, autoHCT autologous hematopoietic cell transplantation, alloHCT allogeneic hematopoietic cell transplantation, chemoRx chemotherapy, TBI total body irradiation, ChemoR chemoresistance, MAC myeloablative conditioning, RIC reduced intensity conditioning, NMAC non-myeloablative conditioning, FL follicular lymphoma, tFL transformed follicular lymphoma, DLBCL diffuse large B cell lymphoma, BL Burkitt lymphoma, SLL small lymphocytic lymphoma, MZL marginal zone lymphoma, EBMT European Bone Marrow Transplant Registry, CBMTG Canadian Blood and Marrow Transplant Group, CIBMTR Center for International Blood and Marrow Transplant Research, MRD matched related donor, URD unrelated donor.